VIDEO: Study investigates HER2-low, ultralow eligibility for trastuzumab deruxtecan
SAN ANTONIO — In this video, Raza Hoda, MD, discusses results from the DESTINY-Breast04 and DESTINY-Breast06 trials presented at San Antonio Breast Cancer Symposium.
In this retrospective study, Hoda and colleague, Patrick McIntire, MD, evaluated patients with hormone receptor-positive, HER2-low, HER2-ultralow and HER2-null metastatic breast cancer to indicate patient eligibility for HER2-directed antibody-drug conjugates, such as trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo).
“We were looking at is there any difference in the clinical and pathologic variations between these patients, and there isn’t any,” Hoda, staff pathologist and assistant professor of pathology at Cleveland Clinic Lerner College of Medicine, said.
Reference:
- Hoda R, et al. Abstract P1-07-10. Presented at: San Antonio Breast Cancer Symposium; Dec. 10-13, 2024; San Antonio.
Collapse
Healio Interviews